Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Decreases By 21.5%

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 48,500 shares, a decline of 21.5% from the February 28th total of 61,800 shares. Approximately 0.1% of the company's shares are sold short. Based on an average daily volume of 75,800 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of SOPHiA GENETICS by 6.5% during the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company's stock worth $2,180,000 after acquiring an additional 42,689 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock worth $68,000 after purchasing an additional 4,115 shares during the last quarter. Federated Hermes Inc. boosted its holdings in SOPHiA GENETICS by 40.5% in the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock valued at $312,000 after purchasing an additional 28,819 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $70,000. Finally, Green Alpha Advisors LLC raised its holdings in SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company's stock worth $145,000 after purchasing an additional 25,686 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

SOPHiA GENETICS Stock Down 8.0 %

Shares of SOPHiA GENETICS stock traded down $0.24 during trading hours on Friday, reaching $2.76. 82,838 shares of the company were exchanged, compared to its average volume of 67,583. The firm has a market cap of $184.06 million, a PE ratio of -2.53 and a beta of 1.01. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. SOPHiA GENETICS has a 1 year low of $2.70 and a 1 year high of $6.28. The stock's fifty day moving average is $3.54 and its 200 day moving average is $3.47.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.23). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The company had revenue of $17.73 million during the quarter, compared to the consensus estimate of $17.71 million. As a group, equities research analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on SOPH shares. BTIG Research set a $5.00 price target on SOPHiA GENETICS in a research report on Thursday, March 6th. Craig Hallum initiated coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a "buy" rating and a $11.00 target price for the company.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.